FDA Approves New Treatment for Eye Inflammation
Vigamox (PDF), a preservative-free ophthalmic solution containing 0.5 percent moxifloxacin, was approved Wednesday by the Food and Drug Administration. Alcon Inc. will market the product for the treatment of conjunctivitis caused by susceptible strains of bacteria, including Chlamydia trachomatis.
The recommended procedure for using the product is to instill one drop of the solution in the affected eye three times a day for seven days.
According to the product's labeling, the solution must not be used in patients with a hypersensitivity to moxifloxacin or any other quinolone. The company stated that the solution may be used in children as young as 1 year old.
Various ocular reactions, including dry eye and pain, have been reported in up to 6 percent of patients who used the product. Also, up to 4 percent of patients have had fever, increased cough, or inflammation of the middle ear, nasal mucous membranes, or pharynx from using the ophthalmic solution.
Alcon said it expected to have its new product available within several weeks.